World Conference on Lung Cancer Monday Press Conference: Clinical Research Results and Gender Differences in Lung Cancer Survival
TORONTO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- At today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC), conference co-president Dr. Andrea Bezjak, M.D., FRCPC, MSc, professor in the Departments of Radiation Oncology and Health Policy, Management and Evaluation at the University of Toronto and staff radiation oncologist at Princess Margaret Cancer Centre, summarized the wide-ranging study topics presented in today’s conference, from significant clinical research findings to gender differences in lung cancer survival.
IMpower132 study shows atezolizumab in combination with carboplatin and pemetrexed improves survival in Stage IV non-squamous NSCLC
Recent findings from the IMpower132 study, presented by Vassiliki A. Papadimitrakopoulou, M.D., chief of the Section of Thoracic Medical Oncology at MD Anderson Cancer Center, demonstrate that the use of atezolizumab in combination with carboplatin as first-line therapy and pemetrexed as maintenance therapy improves progression-free survival (PFS) in patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).
Though survival data is not yet mature, preliminary results indicate an improvement in overall survival (OS) with the three-drug combination. These results are significant because they indicate that the historically poor median OS of 12 months found with current standard-of-care treatment options can be improved upon.
“The findings from IMpower132 indicate that the addition of atezolizumab to a backbone of carboplatin and pemetrexed chemotherapy provides better clinical efficacy than carboplatin and pemetrexed alone…offering a valuable treatment option that prolongs survival for patients with Stage IV non-squamous NSCLC,” said Dr. Papadimitrakopoulou.
Read the full press release here.
Entrectinib produced a clinically meaningful response in locally advanced or metastatic ROS1 fusion-positive NSCLC
Recent findings demonstrate entrectinib, an oral, potent and selective ROS1/NTRK/ALK tyrosine kinase inhibitor, produced a clinically meaningful and durable systemic response in patients with and without central nervous system (CNS) metastases, according to results presented today by Robert C. Doebele, M.D., Ph.D., of the Division of Medical Oncology at the University of Colorado.
The results comprised of an integrated analysis of three studies, ALKA, STARTRK-1 and STARTRK-2, and included 53 patients. The response rate was 77.4 percent, with median duration of response of 24.6 months. The median progression free survival was 26.3 months for patients without CNS metastases and 13.6 months for patients with CNS metastases. Entrectinib was tolerable with a manageable safety profile.
"The data look very exciting. The hope is that entrectinib could replace crizotinib as a first-line therapy against ROS1-positive NSCLC," said Dr. Doebele.
Read the full press release here.
Dr. Lucy Kalanithi, opening plenary speaker at the IASLC World Conference on Lung Cancer, examines how serious illness can create important sense of meaning for HCPs, caregivers and patients
The importance of having a professional and personal sense of meaning when dealing with serious illness, such as lung cancer, was the topic of today’s opening Plenary Session, “Patients First.” Speaker Lucy Kalanithi, M.D., offered a unique dual perspective as a physician and a caregiver who lost her young spouse to Stage IV lung cancer.
“When you are a medical professional who works with an illness as serious as lung cancer, that challenge comes with an inherent opportunity to add value and a sense of meaning not only to your patients’ lives but also to your own,” said Dr. Kalanithi. “This profession is not just a job, it’s a calling.”
Dr. Kalanithi’s debut presentation at the WCLC, When Breath Becomes Air, shares the title of her husband’s number-one New York Times best-selling memoir, for which she wrote the epilogue.
Read the full press release here.
Study shows outdoor air pollution exposure significantly higher in women non-smokers with lung cancer than women smokers with lung cancer
Findings from a recent study, presented by Renelle L. Myers, British Columbia Cancer Agency, Vancouver, demonstrate that female lung cancer patients who have never smoked have significantly greater exposure rates to outdoor air pollution than female lung cancer patients with a history of smoking.
The results of the study showed median air pollution exposure of never-smoker cancer patients was more than double that of ever-smokers with lung cancer. Interestingly, never-smokers with the highest levels of ambient particulate matter exposure were 74 percent women.
“The results of this study underscore the importance of factoring outdoor air pollution into lung cancer development among women, particularly those who have never smoked,” said Myers. “Although long-term exposure to ambient particulate matter has been associated with an increased risk of developing lung cancer…there is currently no lung cancer screening risk prediction model that includes air pollution as an individual risk factor in its calculation.”
Read the full press release here.
Women with non-small cell lung cancers live longer than men, WCLC study shows
Women diagnosed with non-small cell lung cancers (NSCLC) live longer than their male counterparts, according to results of a SWOG study presented today by Kathy Albain, M.D., the Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine.
Dr. Albain and her SWOG team studied 981 patients newly diagnosed with Stage I, II, or III NSCLC and grouped them into four cohorts based on sex and smoking history. Regardless of smoking history or any other factor, women in the trial had significantly better overall survival (OS) rates compared to men. The analysis found that female never-smokers and female ever-smokers had significantly better OS compared to male never-smokers and male ever-smokers.
“Women with NSCLC live longer, even when we control for every factor that might influence survival in NSCLC, including tobacco and other exposures, lifestyle factors, disease stage, treatment, tumor biology and hormonal factors,” said Dr. Albain. “Additional study is needed to further investigate favorable survival for women in this population, and our large clinical trials need to be equally balanced for women.”
Read the full press release here.
Smoking cessation services widely accepted during lung cancer screenings
A recent study, presented by William Evans, M.D., FRCPC, professor emeritus, McMaster University Department of Oncology, and Clinical Advisor, Smoking Cessation, Cancer Care Ontario, found that smoking cessation services (SCS) offered at the time of lung cancer screening had a high acceptance rate by current smokers.
Of 808 individuals eligible for lung cancer screening, 63 percent were identified as current smokers. Of screen-eligible current smokers, 89 percent accepted hospital-based cessation counseling, and 88 percent of those who had a baseline low-dose computed tomography (CT) in the reporting period attended a hospital-based counselling session.
“It is important to seize the opportunity to discuss smoking cessation with those attending a screening program,” said Dr. Evans. “The motivation of the individuals coming in for screening, combined with the approaches taken by the nurse navigator, has made the program successful. By taking an empathetic approach, we’ve been able to help current smokers get the resources they need to help with their addiction to nicotine.”
Read the full press release here.
Livestreams of the daily press conferences are available here.
About the WCLC
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit http://wclc2018.iaslc.org/. Follow the conference on social media with: #WCLC2018.
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.
firstname.lastname@example.org| +1 617-657-1305
Becky Bunn, MSc
Public Relations Manager
Becky.Bunn@IASLC.org | +1 720-254-9509
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
TESARO Announces Data Presentations at ESMO 2018 Congress20.10.2018 07:30 | Pressemelding
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer PRIMA safety data for individualized niraparib dose regimen presented Top-line results for PRIMA trial of niraparib in first-line ovarian cancer regardless of biomarker status expected in late 2019 MUNICH, Germany, Oct. 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today summarized updated Phase 1 GARNET data of TSR-042 (anti-PD-1 antibody) in patients with recurrent or advanced microsatellite instability high (MSI-H) endometrial cancer presented during the European Society for Medical Oncology (ESMO) Congress. Blinded, pooled interim safety data from the Phase 3 PRIMA trial of niraparib in patients with first-line ovarian cancer regardless of biomarker status were also presented in a poster discussion session and additional data from the QUADRA trial of niraparib for treatment of late-li
The Navigators Group, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger19.10.2018 22:01 | Pressemelding
STAMFORD, Conn., Oct. 19, 2018 (GLOBE NEWSWIRE) -- The Navigators Group, Inc. (NASDAQ:NAVG) (“Navigators” or the “Company”) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with its previously announced merger with a direct wholly owned subsidiary (“Merger Sub”) of The Hartford Financial Services Group, Inc. (“The Hartford”), expired at 11:59 p.m. Eastern Time on October 18, 2018. The expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the merger, which remains subject to other closing conditions in the Agreement and Plan of Merger, dated as of August 22, 2018, by and among the Company, The Hartford and Merger Sub. About Navigators The Navigators Group, Inc. (NASDAQ: NAVG) (“Navigators” or the “Company”) is a global specialty insurance holding company. We provide customized insurance solutions designed to protect clients from the complex risk
ATTO Technology introduces the XstreamCORE® FC 7600 32Gb Fibre Channel to 12Gb SAS Hardware Accelerated Storage Controller19.10.2018 15:00 | Pressemelding
AMHERST, N.Y., Oct. 19, 2018 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for 30 years, announces availability of the ATTO XstreamCORE® FC 7600 storage controller. ATTO XstreamCORE FC 7600 is a standalone, accelerated storage controller that connects any external SAS device, such as a JBOD of HDDs or SSDs, a RAID array or external tape devices, and presents them isolated to individual hosts or shared over a Fibre Channel SAN fabric. It includes ATTO exclusive technologies, ATTO xCORE hardware acceleration processor and ATTO intelligent Bridging Architecture™, that combine to keep latency astonishingly low at three microseconds. For less than the price of a performance server, XstreamCORE FC 7600 enables up to 64 Fibre Channel connected clients to remotely access and share up to 240 SAS/SATA SSD or HDD devices via JBOD or JBOF at direct attached speeds with consistent, d
Biome Grow Introduces PEI Brand, Red Sands Craft Cannabis Co.19.10.2018 13:30 | Pressemelding
TORONTO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE:BIO) (FSE:6OTA) is pleased to introduce its fifth subsidiary company and brand, Red Sands Craft Cannabis Co. (“Red Sands”). Red Sands is located in Prince Edward Island (PEI) and will service both the local and tourist markets in that province with locally produced and regionally grown cannabis products. The Red Sands Craft Cannabis Co. brand reflects PEI’s iconic red sand beaches and the craft goods and services that are produced locally. Visually, it balances the vibrant, energetic colours with the calm nature that PEI is known for, setting the stage for the tailored cannabis products that Red Sands will offer. Though the smallest Canadian province both in terms of land area and population, with approximately 153,000 residents living on the Island, the province has a robust tourism industry. In 2017, the province set records with more than 1,000,000 overnight stays, by an estimated 1.56 million
CORRECTION - Elite Petro & Gas broadens financial services and signs a deal with Tabarak Investment Capital Limited18.10.2018 23:35 | Pressemelding
DUBAI, United Arab Emirates, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Today the President of Elite Petro & Gas, Mr. George Matharu and the President of Tabarak Investment Capital Limited (Investment Bank), Dr. Mohamed Ahmadi announced a deal in which the two companies will use their combined resources to execute physical commodity trades, and provide banking and finance facilities for oil and gas transactions. The alliance between the two entities will also allow compliance related activities to be carried out from two major international hubs of London and Dubai. This increases the international presence of both companies. Additionally, Elite Petro & Gas (“EPG”) has recently formed relationships with the owners of a number of high profile European, South American and Chinese projects, which EPG and Tabarak can work on together. Tabarak Investment Capital Limited is a regulated investment bank by Dubai Financial Services Authority and incorporated in the Dubai International Financial Centre.
Partnership Between Zaiput Flow Technologies and ThalesNano Set to Improve Process Intensification18.10.2018 15:21 | Pressemelding
BUDAPEST, Hungary and WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zaiput Flow Technologies, a global leader in separation, and ThalesNano, the world leader in bench-top flow chemistry reactors, recently signed a distribution agreement and entered into a technology partnership that exploits the benefits of their combined technologies. Under the distribution Zaiput liquid-liquid phase separators and back pressure regulators are available via ThalesNano in Europe and a number of other countries on a non-exclusive basis, either separately or as part of a bundled offering with ThalesNano’s own microflow reactors. Within the framework of the technology partnership the companies will collaborate to promote adoption of the combined use of their technologies. “We are very excited to work with ThalesNano to offer better-integrated flow chemistry systems to our customers and streamline the work of both novice and experienced users in the flow chemistry space,” said Zaiput CEO, Dr. Andrea Ad
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom